- Home
- MHUA vs NLSP Comparison
MHUA vs NLSP Comparison
Compare MHUA & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- NLSP
- Stock Information
- Founded
- MHUA 1990
- NLSP 2015
- Country
- MHUA China
- NLSP Switzerland
- Employees
- MHUA N/A
- NLSP N/A
- Industry
- MHUA Medical Specialities
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- NLSP Health Care
- Exchange
- MHUA Nasdaq
- NLSP Nasdaq
- Market Cap
- MHUA 12.7M
- NLSP 12.4M
- IPO Year
- MHUA 2022
- NLSP 2021
- Fundamental
- Price
- MHUA $0.36
- NLSP $1.63
- Analyst Decision
- MHUA
- NLSP
- Analyst Count
- MHUA 0
- NLSP 0
- Target Price
- MHUA N/A
- NLSP N/A
- AVG Volume (30 Days)
- MHUA 205.6K
- NLSP 896.7K
- Earning Date
- MHUA 09-19-2025
- NLSP 10-06-2025
- Dividend Yield
- MHUA N/A
- NLSP N/A
- EPS Growth
- MHUA N/A
- NLSP N/A
- EPS
- MHUA 0.29
- NLSP N/A
- Revenue
- MHUA $89,547,563.00
- NLSP N/A
- Revenue This Year
- MHUA N/A
- NLSP N/A
- Revenue Next Year
- MHUA N/A
- NLSP N/A
- P/E Ratio
- MHUA $1.34
- NLSP N/A
- Revenue Growth
- MHUA N/A
- NLSP N/A
- 52 Week Low
- MHUA $0.25
- NLSP $1.30
- 52 Week High
- MHUA $1.17
- NLSP $5.64
- Technical
- Relative Strength Index (RSI)
- MHUA 41.39
- NLSP 36.11
- Support Level
- MHUA $0.37
- NLSP $1.45
- Resistance Level
- MHUA $0.43
- NLSP $1.89
- Average True Range (ATR)
- MHUA 0.03
- NLSP 0.18
- MACD
- MHUA -0.00
- NLSP -0.03
- Stochastic Oscillator
- MHUA 13.12
- NLSP 17.82
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.